AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 37188309 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified in detail)
Number of subjects: 0
Study 37188389 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasonography
Number of subjects: 280
Study 37188389 — intervention group
Group type: COMPARATOR
Intervention: Palpation
Number of subjects: 280
Study 37188468 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine 1.5 mg/kg
Number of subjects: 250
Study 37188468 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine 3 mg/kg
Number of subjects: 250
Study 37188468 — intervention group
Group type: COMPARATOR
Intervention: Dextrose 5% in water placebo
Number of subjects: 250
Study 37188469 — intervention group
Group type: EXPERIMENTAL
Intervention: Culturally competent intervention
Number of subjects: 0
Study 37188469 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 37188668 — intervention group
Group type: EXPERIMENTAL
Intervention: Nivolumab 3 mg/kg every 2 weeks and ipilimumab 1 mg/kg every 6 weeks
Number of subjects: 40
Study 37188782 — intervention group
Group type: EXPERIMENTAL
Intervention: GD2-CAR.15 NKTs
Number of subjects: 12
Study 37188783 — intervention group
Group type: EXPERIMENTAL
Intervention: Intratumoral delivery of oncolytic virus DNX-2401 followed by intravenous anti-PD-1 antibody pembrolizumab
Number of subjects: 49
Study 37188890 — intervention group
Group type: EXPERIMENTAL
Intervention: Monopolar tungsten needle electrodes and PTFE-coated spatula electrodes
Number of subjects: 132
Study 37188890 — intervention group
Group type: COMPARATOR
Intervention: Conventional dissection with sharp instruments and coagulation with uncoated steel electrodes
Number of subjects: 132
Study 37188895 — intervention group
Group type: EXPERIMENTAL
Intervention: napabucasin (480 mg/day) plus sorafenib (800 mg/day)
Number of subjects: 6
Study 37189057 — intervention group
Group type: EXPERIMENTAL
Intervention: Betadine-coated gastrostomy tube
Number of subjects: 50
Study 37189057 — intervention group
Group type: COMPARATOR
Intervention: Control group (non-Betadine-coated gastrostomy tube)
Number of subjects: 50
Study 37189057 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 50
Study 37189057 — intervention group
Group type: EXPERIMENTAL
Intervention: Delta CRP
Number of subjects: 50
Study 37189075 — intervention group
Group type: EXPERIMENTAL
Intervention: First-line pembrolizumab plus chemotherapy in treatment-naïve LCC (n=27)
Number of subjects: 60
Study 37189075 — intervention group
Group type: EXPERIMENTAL
Intervention: First-line pembrolizumab plus chemotherapy in treatment-naïve LCNEC (n=10)
Number of subjects: 60
Study 37189075 — intervention group
Group type: EXPERIMENTAL
Intervention: Subsequent-line pembrolizumab with or without chemotherapy in pre-treated LCC (n=23)
Number of subjects: 60
Study 37189075 — intervention group
Group type: EXPERIMENTAL
Intervention: Subsequent-line pembrolizumab with or without chemotherapy in pre-treated LCNEC (n=23)
Number of subjects: 60
Study 37189085 — intervention group
Group type: EXPERIMENTAL
Intervention: Glucocorticoids (methylprednisolone intravenously for 3 days)
Number of subjects: 0
Study 37189085 — intervention group
Group type: COMPARATOR
Intervention: Normal treatment
Number of subjects: 0
Study 37189091 — intervention group
Group type: EXPERIMENTAL
Intervention: AUEC enrollment
Number of subjects: 533
Study 37189091 — intervention group
Group type: COMPARATOR
Intervention: MC enrollment
Number of subjects: 533
Study 37189100 — intervention group
Group type: EXPERIMENTAL
Intervention: Winter hiking intervention with free access to a regional winter hiking challenge and winter traction cleats in the second study.
Number of subjects: 104
Study 37189100 — intervention group
Group type: EXPERIMENTAL
Intervention: Winter hiking intervention (without traction cleats in the first study).
Number of subjects: 104
Study 37189100 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified in detail).
Number of subjects: 104
Study 37189128 — intervention group
Group type: EXPERIMENTAL
Intervention: Cigarette smoking
Number of subjects: 1279
Study 37189128 — intervention group
Group type: EXPERIMENTAL
Intervention: Snuff use
Number of subjects: 1279
Study 37189128 — intervention group
Group type: EXPERIMENTAL
Intervention: Older age
Number of subjects: 1279
Study 37189128 — intervention group
Group type: EXPERIMENTAL
Intervention: Female gender
Number of subjects: 1279
Study 37189149 — intervention group
Group type: EXPERIMENTAL
Intervention: PRISM-AC intervention (skills-based training program with four 30-60 min sessions, family meeting, smartphone app, and advance care planning module)
Number of subjects: 144
Study 37189149 — intervention group
Group type: COMPARATOR
Intervention: Usual, non-directive, supportive care without PRISM-AC (control arm)
Number of subjects: 144
Study 37189151 — intervention group
Group type: EXPERIMENTAL
Intervention: miR-200-sign-up
Number of subjects: 107
Study 37189151 — intervention group
Group type: COMPARATOR
Intervention: miR-200-sign-down
Number of subjects: 107
Study 37189166 — intervention group
Group type: EXPERIMENTAL
Intervention: Hospital-level education intervention designed to reduce anastomotic leak, including online learning, patient risk stratification, and an in-theatre checklist.
Number of subjects: 0
Study 37189166 — intervention group
Group type: COMPARATOR
Intervention: Not applicable (control group not explicitly mentioned).
Number of subjects: 0
Study 37189171 — intervention group
Group type: EXPERIMENTAL
Intervention: Novel medication alerts encouraging collaboration between prescribers and expert pharmacists in anticoagulation clinics.
Number of subjects: 0
Study 37189171 — intervention group
Group type: EXPERIMENTAL
Intervention: Alerts for newly prescribed inappropriate DOACs.
Number of subjects: 0
Study 37189171 — intervention group
Group type: EXPERIMENTAL
Intervention: Existing prescription notifications for inappropriate DOACs.
Number of subjects: 0
Study 37189173 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive assessment using self-rated questionnaires (Perceived Deficits Questionnaire, Hospital Anxiety and Depression Scale, Davidson Trauma Scale) and comprehensive neuropsychological evaluation.
Number of subjects: 80
Study 37189173 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-rated questionnaires for emotional state assessment.
Number of subjects: 80
Study 37189173 — intervention group
Group type: EXPERIMENTAL
Intervention: Perceived cognitive deficit measure.
Number of subjects: 80
Study 37189173 — intervention group
Group type: EXPERIMENTAL
Intervention: Demographic and clinical data analysis.
Number of subjects: 80
Study 37189190 — intervention group
Group type: EXPERIMENTAL
Intervention: Parent Intervention (PI)
Number of subjects: 89
Study 37189190 — intervention group
Group type: EXPERIMENTAL
Intervention: Summer Camp (SCV)
Number of subjects: 89
Study 37189190 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of Summer Camp and Parent Intervention (SCV+PI)
Number of subjects: 89
Study 37189190 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 89
Study 37189190 — intervention group
Group type: EXPERIMENTAL
Intervention: Summer Programming (SCV and PI)
Number of subjects: 89
Study 37189190 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall Efficacy
Number of subjects: 89
Study 37189224 — intervention group
Group type: EXPERIMENTAL
Intervention: Local Anesthesia (LA)
Number of subjects: 76
Study 37189224 — intervention group
Group type: COMPARATOR
Intervention: Brachial Plexus Block (BP)
Number of subjects: 76
Study 37189240 — intervention group
Group type: EXPERIMENTAL
Intervention: Probiotics and nutritional supplements
Number of subjects: 0
Study 37190160 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary rice bran
Number of subjects: 40
Study 37190160 — intervention group
Group type: COMPARATOR
Intervention: Control AIN93M
Number of subjects: 40
Study 37190238 — intervention group
Group type: EXPERIMENTAL
Intervention: Nursing calls focused on advance care planning (ACP), symptom management, and care coordination
Number of subjects: 218
Study 37190598 — intervention group
Group type: EXPERIMENTAL
Intervention: TTFields combined with TMZ
Number of subjects: 1
Study 37190598 — intervention group
Group type: COMPARATOR
Intervention: TMZ alone (implied control)
Number of subjects: 1
Study 37190665 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional therapy plus upper limb robot-assisted therapy (UL-RAT) using an exoskeleton robotic system (Armeo)
Number of subjects: 84
Study 37190665 — intervention group
Group type: COMPARATOR
Intervention: Conventional therapy (CT)
Number of subjects: 84
Study 37190883 — intervention group
Group type: EXPERIMENTAL
Intervention: Intracoronary infusion of autologous bone-marrow-derived mononuclear cells with Impella CP device support
Number of subjects: 20
Study 37190970 — intervention group
Group type: EXPERIMENTAL
Intervention: Digital solution (Noona)
Number of subjects: 142
Study 37190970 — intervention group
Group type: COMPARATOR
Intervention: Phone calls
Number of subjects: 142
Study 37190970 — intervention group
Group type: EXPERIMENTAL
Intervention: Both modalities
Number of subjects: 142
Study 37190970 — intervention group
Group type: EXPERIMENTAL
Intervention: Digital solution
Number of subjects: 142
Study 37191077 — intervention group
Group type: EXPERIMENTAL
Intervention: Vericiguat
Number of subjects: 0
Study 37191154 — intervention group
Group type: EXPERIMENTAL
Intervention: High-intensity care (HIC) strategy of guideline-directed medical therapies (GDMT) up-titration
Number of subjects: 1078
Study 37191154 — intervention group
Group type: COMPARATOR
Intervention: Usual care (UC)
Number of subjects: 1078
Study 37191188 — intervention group
Group type: EXPERIMENTAL
Intervention: Arginine methylation inhibitors
Number of subjects: 0
Study 37191188 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 37191339 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 h of SOP training
Number of subjects: 216
Study 37191339 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 216
Study 37191612 — intervention group
Group type: EXPERIMENTAL
Intervention: Burst SCS
Number of subjects: 29
Study 37191612 — intervention group
Group type: COMPARATOR
Intervention: L2 DRGS
Number of subjects: 29
Study 37191681 — intervention group
Group type: EXPERIMENTAL
Intervention: Positron emission tomography (PET) using 18F-PFPN
Number of subjects: 76
Study 37191681 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 76
Study 37191697 — intervention group
Group type: EXPERIMENTAL
Intervention: Active tDCS (30 min at 2 mA, anode over F3, cathode over F4) for 6 weeks, 5 sessions/week
Number of subjects: 11
Study 37191697 — intervention group
Group type: COMPARATOR
Intervention: Sham tDCS (resembled active tDCS but without intermittent stimulation)
Number of subjects: 11
Study 37191738 — intervention group
Group type: EXPERIMENTAL
Intervention: Upadacitinib 15 mg once daily
Number of subjects: 100
Study 37191738 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study 37191995 — intervention group
Group type: COMPARATOR
Intervention: Sit-to-stand desk
Number of subjects: 66
Study 37191995 — intervention group
Group type: COMPARATOR
Intervention: Treadmill desk
Number of subjects: 66
Study 37192040 — intervention group
Group type: EXPERIMENTAL
Intervention: BI 655064 120 mg
Number of subjects: 121
Study 37192040 — intervention group
Group type: EXPERIMENTAL
Intervention: BI 655064 180 mg
Number of subjects: 121
Study 37192040 — intervention group
Group type: EXPERIMENTAL
Intervention: BI 655064 240 mg
Number of subjects: 121
Study 37192040 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 121
Study 37192167 — intervention group
Group type: EXPERIMENTAL
Intervention: Sex chromosome aneuploidies (XX, XXX, XY, XXY, XYY, XXYY)
Number of subjects: 197
Study 37192176 — intervention group
Group type: EXPERIMENTAL
Intervention: TAU + e-CBTi
Number of subjects: 60
Study 37192176 — intervention group
Group type: COMPARATOR
Intervention: TAU + trazodone
Number of subjects: 60
Study 37192190 — intervention group
Group type: EXPERIMENTAL
Intervention: Community Mobilization and Community Incentivization (CoMIC)
Number of subjects: 0
Study 37192190 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive inclusive community engagement and demand creation strategies tied to conditioned short term tangible incentives
Number of subjects: 0
Study 37192204 — intervention group
Group type: EXPERIMENTAL
Intervention: Chronic postsurgical pain at 3 months after surgery
Number of subjects: 767
Study 37192204 — intervention group
Group type: EXPERIMENTAL
Intervention: Chronic postsurgical pain at 6 months after surgery
Number of subjects: 767
Study 37192204 — intervention group
Group type: EXPERIMENTAL
Intervention: Chronic postsurgical pain at 12 months after surgery
Number of subjects: 767
Study 37192204 — intervention group
Group type: EXPERIMENTAL
Intervention: Neuropathic phenotype pain at 3 months
Number of subjects: 767
Study 37192204 — intervention group
Group type: EXPERIMENTAL
Intervention: Neuropathic phenotype pain at 6 months
Number of subjects: 767
Study 37192204 — intervention group
Group type: EXPERIMENTAL
Intervention: Neuropathic phenotype pain at 12 months
Number of subjects: 767
Study 37192282 — intervention group
Group type: EXPERIMENTAL
Intervention: Healthy behavior text messaging (yes)
Number of subjects: 488
Study 37192282 — intervention group
Group type: EXPERIMENTAL
Intervention: Prompted self-measured blood pressure monitoring and feedback (weekly)
Number of subjects: 488
Study 37192282 — intervention group
Group type: EXPERIMENTAL
Intervention: Prompted self-measured blood pressure monitoring and feedback (daily)
Number of subjects: 488
Study 37192282 — intervention group
Group type: EXPERIMENTAL
Intervention: Facilitated primary care provider appointment scheduling and transportation (yes)
Number of subjects: 488
Study 37192282 — intervention group
Group type: COMPARATOR
Intervention: Healthy behavior text messaging (no)
Number of subjects: 488
Study 37192282 — intervention group
Group type: COMPARATOR
Intervention: Prompted self-measured blood pressure monitoring and feedback (no)
Number of subjects: 488
Study 37192282 — intervention group
Group type: COMPARATOR
Intervention: Facilitated primary care provider appointment scheduling and transportation (no)
Number of subjects: 488
Study 37192288 — intervention group
Group type: EXPERIMENTAL
Intervention: Cardiac scale measurements (daily)
Number of subjects: 300
Study 37192288 — intervention group
Group type: EXPERIMENTAL
Intervention: Composite index derived from noninvasive hemodynamic biomarkers
Number of subjects: 300
Study 37192288 — intervention group
Group type: COMPARATOR
Intervention: Simple weight-based rule-of-thumb algorithms
Number of subjects: 300
Study 37192308 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcatheter Aortic Valve Replacement (TAVR)
Number of subjects: 200
Study 37192310 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcatheter Aortic Valve Replacement (TAVR)
Number of subjects: 706
Study 37192310 — intervention group
Group type: COMPARATOR
Intervention: Medical management (Medical-Mod)
Number of subjects: 706
Study 37192425 — intervention group
Group type: EXPERIMENTAL
Intervention: Opioid-sparing multimodal analgesia (ketorolac, orphenadrine, and gabapentin)
Number of subjects: 0
Study 37192425 — intervention group
Group type: COMPARATOR
Intervention: Opioid-based regimen
Number of subjects: 0
Study 37192437 — intervention group
Group type: EXPERIMENTAL
Intervention: Pirtobrutinib monotherapy
Number of subjects: 90
Study 37192443 — intervention group
Group type: EXPERIMENTAL
Intervention: Phosphodiesterase-4 Inhibition
Number of subjects: 0
Study 37192445 — intervention group
Group type: EXPERIMENTAL
Intervention: Noninvasive respiratory support
Number of subjects: 0
Study 37192445 — intervention group
Group type: COMPARATOR
Intervention: Control group (standard care)
Number of subjects: 0
Study 37192642 — intervention group
Group type: EXPERIMENTAL
Intervention: MDMA (100 mg)
Number of subjects: 30
Study 37192642 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 37192697 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrathin-strut biodegradable polymer Sirolimus-eluting stents (BP-SES)
Number of subjects: 3397
Study 37192697 — intervention group
Group type: COMPARATOR
Intervention: Thin-strut durable polymer Everolimus-eluting stents (DP-EES)
Number of subjects: 3397
Study 37192698 — intervention group
Group type: EXPERIMENTAL
Intervention: AI image analysis report (EchoGo Pro)
Number of subjects: 2500
Study 37192698 — intervention group
Group type: COMPARATOR
Intervention: Current practice (control group)
Number of subjects: 2500
Study 37192729 — intervention group
Group type: EXPERIMENTAL
Intervention: HuSC1-39 (anti-TF)
Number of subjects: 0
Study 37192729 — intervention group
Group type: EXPERIMENTAL
Intervention: Dual-targeting anti-TF&TGFβR fusion protein
Number of subjects: 0
Study 37192729 — intervention group
Group type: EXPERIMENTAL
Intervention: anti-TF or TF-knockout
Number of subjects: 0
Study 37192729 — intervention group
Group type: EXPERIMENTAL
Intervention: TF-high TNBC cells treated with anti-TF
Number of subjects: 0
Study 37192729 — intervention group
Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 0
Study 37192741 — intervention group
Group type: EXPERIMENTAL
Intervention: Nomogram developed using levels of 45 cytokines (CX3CL1, GZMB, IL4, IL6, PDGFAA) on days 1-2 after CAR-T cell infusion.
Number of subjects: 214
Study 37192741 — intervention group
Group type: EXPERIMENTAL
Intervention: Nomogram validation in external cohorts (MM).
Number of subjects: 214
Study 37192741 — intervention group
Group type: EXPERIMENTAL
Intervention: Nomogram validation in external cohorts (ALL/NHL).
Number of subjects: 214
Study 37192754 — intervention group
Group type: EXPERIMENTAL
Intervention: Noradrenaline infusion to increase mean arterial blood pressure (MAP) by a maximum of 30 mmHg to an absolute level of no more than 130 mmHg.
Number of subjects: 36
Study 37192754 — intervention group
Group type: EXPERIMENTAL
Intervention: Noradrenaline infusion to increase MAP.
Number of subjects: 36
Study 37192785 — intervention group
Group type: EXPERIMENTAL
Intervention: Ropivacaine via bilateral cESP catheters
Number of subjects: 9
Study 37192785 — intervention group
Group type: COMPARATOR
Intervention: Saline (control)
Number of subjects: 9
Study 37192994 — intervention group
Group type: EXPERIMENTAL
Intervention: AG-920 (articaine ophthalmic solution)
Number of subjects: 240
Study 37192994 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 240
Study 37193282 — intervention group
Group type: EXPERIMENTAL
Intervention: Sleep
Number of subjects: 53
Study 37193282 — intervention group
Group type: COMPARATOR
Intervention: Wake
Number of subjects: 53
Study 37193393 — intervention group
Group type: EXPERIMENTAL
Intervention: 5-h TIB during sleep restriction
Number of subjects: 57
Study 37193393 — intervention group
Group type: EXPERIMENTAL
Intervention: 6.5-h TIB during sleep restriction
Number of subjects: 57
Study 37193393 — intervention group
Group type: COMPARATOR
Intervention: 9-h TIB during baseline and recovery nights
Number of subjects: 57
Study 37193393 — intervention group
Group type: EXPERIMENTAL
Intervention: Drift diffusion modelling (DDM) measures
Number of subjects: 57
Study 37193586 — intervention group
Group type: EXPERIMENTAL
Intervention: Reintubated infants after extubation
Number of subjects: 55
Study 37193586 — intervention group
Group type: EXPERIMENTAL
Intervention: Criteria used for reintubation in clinical practice
Number of subjects: 55
Study 37193776 — intervention group
Group type: EXPERIMENTAL
Intervention: EPI (ExoDx Prostate test)
Number of subjects: 1049
Study 37193776 — intervention group
Group type: COMPARATOR
Intervention: SOC (Standard of Care)
Number of subjects: 1049
Study 37194008 — intervention group
Group type: EXPERIMENTAL
Intervention: Implementation of IPC measures (poor, moderate, thorough)
Number of subjects: 0
Study 37194008 — intervention group
Group type: COMPARATOR
Intervention: Thorough implementation of IPC measures
Number of subjects: 0
Study 37194051 — intervention group
Group type: EXPERIMENTAL
Intervention: Electronic screening for tobacco use during COVID
Number of subjects: 3904
Study 37194051 — intervention group
Group type: EXPERIMENTAL
Intervention: Electronic screening for any substance use during COVID
Number of subjects: 3904
Study 37194051 — intervention group
Group type: EXPERIMENTAL
Intervention: Electronic screening for suicidal ideation during COVID
Number of subjects: 3904
Study 37194051 — intervention group
Group type: COMPARATOR
Intervention: Electronic screening for depression
Number of subjects: 3904
Study 37194051 — intervention group
Group type: COMPARATOR
Intervention: Electronic screening for anxiety
Number of subjects: 3904
Study 37194051 — intervention group
Group type: COMPARATOR
Intervention: Electronic screening for alcohol use
Number of subjects: 3904
Study 37194051 — intervention group
Group type: COMPARATOR
Intervention: Electronic screening for cannabis use
Number of subjects: 3904
Study 37194068 — intervention group
Group type: EXPERIMENTAL
Intervention: Individualized dosing of follitropin delta (average daily dose 11.0 ± 1.6 µg, duration 10.3 ± 1.6 days)
Number of subjects: 104
Study 37194068 — intervention group
Group type: EXPERIMENTAL
Intervention: Individualized dosing of follitropin delta
Number of subjects: 104
Study 37194074 — intervention group
Group type: EXPERIMENTAL
Intervention: Group well child care provided on-site at a maternal substance use disorder treatment program.
Number of subjects: 108
Study 37194074 — intervention group
Group type: COMPARATOR
Intervention: Individual well child care from a nearby pediatric primary care clinic.
Number of subjects: 108
Study 37194089 — intervention group
Group type: EXPERIMENTAL
Intervention: Virtual hospital rounds using telehealth
Number of subjects: 0
Study 37194089 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 0
Study 37194094 — intervention group
Group type: EXPERIMENTAL
Intervention: Secukinumab 150 mg
Number of subjects: 555
Study 37194094 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 555
Study 37194104 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with AN
Number of subjects: 43
Study 37194104 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls (HC)
Number of subjects: 43
Study 37194253 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketamine infusions
Number of subjects: 0
Study 37194253 — intervention group
Group type: COMPARATOR
Intervention: Matched GA TRD sample
Number of subjects: 0
Study 37194288 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcatheter mitral valve replacement (TMVR)
Number of subjects: 97
Study 37194288 — intervention group
Group type: COMPARATOR
Intervention: Guideline-directed medical therapy (GDMT)
Number of subjects: 97
Study 37194394 — intervention group
Group type: EXPERIMENTAL
Intervention: Brepocitinib 30 mg once daily
Number of subjects: 218
Study 37194394 — intervention group
Group type: EXPERIMENTAL
Intervention: Brepocitinib 60 mg once daily
Number of subjects: 218